32 results about "Plasma levels" patented technology

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for excreting dampness and strengthening heart as well as a preparation method and application thereof. The active ingredient of the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3-10 parts of prepared radix aconiti carmichaeli, 5-15 parts of rhizoma zingiberis, 5-15 parts of honey-fried licorice root, 10-30 parts of radix pseudostellariae, 5-15 parts of wine-processed radix cyathulae, 10-30 parts of radix salviae miltiorrhizae, 3-10 parts of pericarpium citri reticulatae, 10-30 parts of rhizoma alismatis and 5-15 parts of radix platycodonis. The traditional Chinese medicine has the effects of tonifying deficiency, dispelling excess, tonifying qi, nourishing yin, excreting dampness and promoting blood circulation, treating root causes by tonifying qi and nourishing yin and treating symptoms by excreting dampness and promoting blood circulation, and achieving the effect of treating both symptoms and root causes. Clinical research shows that the traditional Chinese medicine composition not only can reduce the plasma NT-proBNP level of a patient with ejection fraction retention type heart failure, but also can improve the score of the patient in the Life Quality Scale of Clinical Myocardiopathy Patient, and can be used for treating related diseases such as ejection fraction retention type heart failure and the like.

The present disclosure provides methods and materials related to MANPs. In one embodiment, the present disclosure provides a method for treating hypertension with metabolic syndrome by administering MANPs to a patient in need of such treatment. In one embodiment, the present disclosure provides a method comprising administering MANPs to a patient to lower blood pressure (BP). In one embodiment, the method of the present disclosure is employed to treat patients with low baseline cGMP levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to increase or improve plasma cGMP levels, plasma ANP-like peptide levels, insulin sensitivity, or plasma NEFA levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to lower plasma glucose levels.

This disclosure provides compounds of formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels. [Formula 1] TIFF2026525345000055.tif58128

A preparation method for a novel compound which reduces blood plasma Lp(a) levels, and an intermediate compound of the novel compound. The novel compound is biochemically effective and physiologically active.

The invention discloses application of turmeric volatile oil in preparation of a medicine for preventing and treating acute lung injury. The turmeric volatile oil is extracted and prepared by adopting a steam distillation method, the turmeric volatile oil is subjected to characterization analysis in combination with UPLC (Ultra Performance Liquid Chromatography), and the influence of the turmeric volatile oil on rat lung indexes, lung tissue pathological changes and plasma IL-1beta, TNF-alpha and IL-6 levels is analyzed through LPS (Lipopolysaccharide)-induced replication of a rat acute lung injury model. The turmeric volatile oil is proved to have a remarkable technical effect in treating the acute lung injury. The invention provides new application of turmeric volatile oil in acute lung injury treatment, and provides a new natural medicine source for acute lung injury prevention and treatment.

A method of reducing elevated plasma levels of cholesterol in a subject is disclosed. Also disclosed is a method of treating hypercholesterolemia in a subject. The method comprises administering to the subject an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, in the absence of a cholesterol-lowering drug.

The present disclosure provides compounds of the formula: and pharmaceutically acceptable salts thereof, and compounds of the formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

The present disclosure provides a method of treating or inducing cognitive preservation in a patient with Alzheimer's disease, comprising administering an effective amount of CT1812. The effective amount of CT1812 is 100 mg or 300 mg administered orally once daily. The method demonstrates improvements in cognitive outcomes compared to placebo across multiple measures including ADAS-Cog11, MMSE, ADCS-ADL, and ADCS-CGIC. The method demonstrates improvements in cognitive outcomes in patients with low plasma levels of phosphorylated tau 217 prior to administration.

The present disclosure provides compounds of the formula: and pharmaceutically acceptable salts thereof, and compounds of the formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

This invention relates to the application of chebulic tannic acid in the preparation of drugs for treating atherosclerosis, belonging to the field of atherosclerosis treatment technology. This invention discovers that chebulic tannic acid can specifically bind to the catalytic pocket region of SAHH protein, significantly enhancing its efficiency in hydrolyzing SAH, in ApoE... ‑ / ‑ In a mouse model, chebulic tannic acid significantly reduced plasma SAH levels. Simultaneously, the aortic plaque area decreased in mice treated with chebulic tannic acid. This demonstrates that chebulic tannic acid has a therapeutic effect on atherosclerosis. This invention, by regulating methionine cycle homeostasis through chebulic tannic acid, not only reduces plasma SAH and tHcy levels but also effectively inhibits inflammatory responses and oxidative stress, significantly improving atherosclerosis.

The invention discloses a substituted pyridine propionic acid derivative and application thereof, and belongs to the field of chemical medicines. According to the pyridine propionic acid compound shown in the general formula (I) or the pharmaceutically acceptable salt of the pyridine propionic acid compound, in the compound, an A ring, a B ring and a C ring are independently selected from X1, X2, X3 and X4 are independently selected from N and CR, and at least one of X1, X2, X3 and X4 in the A ring is N. The compound disclosed by the invention has an excellent Lp (a) inhibiting effect and can be used as a medicine for reducing the Lp (a) level of plasma.

The present invention relates to a compound of formula (I), a pharmaceutically acceptable salt, stereoisomer or isotopically labeled substance thereof, a pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating a disease associated with elevated plasma Lp(a) levels.

This invention relates to a 24 hour extended release dosage composition and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet compositions which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release composition of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Bupropion for use in a method for increasing plasma levels of dextromethorphan in a human subject who is an extensive metabolizer of dextromethorphan and in need of dextromethorphan treatment, wherein the use comprises daily co-administration of bupropion with dextromethorphan to the human subject for at least eight consecutive days and wherein, on the eighth day of co-administration of bupropion with dextromethorphan, the AUC0-12 of dextromethorphan is at least 400 ng·h / ml. The application contains 14 additional claims.

A method for providing a prediction as to whether a subject with a cancer exhibits a beneficial response to arginine deprivation therapy including determining the plasma level of arginine in the subject, followed by administering to the subject an arginine deprivation therapy alone or in combination with an anti-cancer agent based on the determined plasma level of arginine. According to some embodiments of the present disclosure, the anti-cancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and a combination thereof.

The present disclosure provides compounds of formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

The invention discloses a MAFLD related biomolecular marker and application, the biomarker is human interleukin-24, and the amino acid sequence of the biomarker is as shown in SEQ ID No.1. The invention reveals that the expression level of human interleukin-24 (IL-24) in the plasma of a patient with the metabolism-related fatty liver disease (MAFLD) is obviously different from that of healthy people for the first time, and large-scale clinical sample verification proves that the plasma IL-24 level of the patient with the MAFLD is obviously reduced. The discovery provides a new molecular marker for clinical diagnosis of MAFLD.

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

This invention discloses the application of Amomum villosum extract in the preparation of drugs for the prevention and treatment of functional dyspepsia, belonging to the field of biotechnology. The extract, when applied to the prevention and / or treatment of functional dyspepsia, can increase plasma levels of motilin (MTL) and gastrin (GAS), promote gastrointestinal motility, significantly improve gastric emptying rate in functional dyspepsia model mice, improve pathological damage to gastric tissue, restore mitochondrial function in gastric tissue, and regulate the expression of related factors in gastric tissue. Even at low doses, it can effectively increase plasma MTL and GAS levels in loperamide hydrochloride-induced functional dyspepsia model mice, improve gastric emptying rate, effectively improve pathological damage to gastric tissue in these mice, and regulate the expression of related factors in the gastric tissue. The raw materials of this invention are derived from natural products, are easy to collect, and have high safety.

The invention belongs to the technical field of biological medicine, and particularly relates to a biomarker and application thereof. The invention finds that when the CECR1 in a biological sample of a hypertrophic cardiomyopathy HCM patient is obviously reduced, the prognosis is poor. The biomarker disclosed by the invention is simple and convenient to sample and can be detected in tissues and blood, and compared with prediction through a model in the prior art, the biomarker disclosed by the invention has the advantages of few detection indexes and quick report result. The biomarker disclosed by the invention is high in accuracy, wherein the blood plasma CECR1 level in a screening queue predicts that AUCs of cardiovascular death of HCM patients and AUCs of SCD are 0.720 (95% CI 0.657-0.783) and 0.798 (95% CI 0.725-0.872) respectively; the blood plasma CECR1 level in the verification queue predicts that the AUCs of the cardiovascular death of the HCM patient and the AUCs of the SCD are 0.757 (95% CI 0.654-0.860) and 0.738 (95% CI 0.587-0.889) respectively; the method can predict cardiovascular death of HCM patients and poor prognosis of SCD, has universality and generalizability, is high in clinical acceptance, improves patient compliance, improves diagnosis efficiency, and provides technical support for precision medical treatment.

This disclosure is based on the formula: [Case 1] This invention provides compounds of TIFF2026524959000037.tif26128 and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels.

Providing a controlled-release formulation containing dorotaberine or its salts, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. [Solution] The present invention provides a controlled-release formulation containing dorotaberine or a salt thereof, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. The present invention provides a once- or twice-daily controlled-release formulation of dorotaberine or a salt thereof that avoids fluctuations in plasma levels, reduces pill burden and side effects through a simplified dosing schedule, and consequently improves patient compliance. The present invention also provides a method for preparing a controlled-release formulation of dorotaberine or a salt thereof. The present invention further provides a controlled-release formulation of dorotaberine or a salt thereof for the treatment of at least one symptom of gastrointestinal, biliary, urinary, and gynecological disorders characterized by a spastic state of smooth muscle in a subject.

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

This disclosure provides compounds of formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels. [Formula 1] TIFF2026524960000122.tif53128

The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng / ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng / ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.

The present disclosure provides compounds of the formula: and pharmaceutically acceptable salts thereof, and compounds of the formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.